REFERENCES
- Boyle P, Maisonneuve P. Napalkov P. Incidence of prostate cancer will double by the year 2030: the argument for prostate cancer: current issues, new approaches. Eur Urol 1996; 29: 3–9.
- Carlsson P. Hjertberg H, Jönsson B, Varenhorst E. The cost of prostatic cancer in a defined population. Scand J Urol Nephrol 1989; 23: 93–96.
- Carlsson P. Spingberg A. Nya medicinska metoder Mom urologin-1. Dyra nya läkemedel bättre an kirurgi? Läkartidningen 1996; 93: 4549–4555.
- Otnes B, Harvei S, Fossa. SD. The burden of prostate cancer from diagnosis until death. Br J Urol 1995; 76: 587–594.
- Rosenthal G. Anticipating the costs and benefits of new technology: a typology for policy. In: Altman SH, Blendon R, eds. Medical technology: the culprit behind health care costs? Proceedings of the 1977 Sun Valley Forum On National Health. 1979.
- SBU Den medicinska utvecklingen i Sverige 1960–1992. SBU-rapport nr. 124,1995, Stockholm 1995.
- SCB Life tables 1990–1994. National Bureau of Statistics, Stockholm 1996.
- Smith JR, Freije D, Carpten JD, et al. Major suscept-ibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371–1374.
- Socialstyrelsen. Hälso- och sjukvirdsstatistisk arsbok 1995.
- Socialstyrelsen. Medicinsk Faktadatabas, MARS, State of the Art: Prostatacancer. Socialstyrelsen 1996.